Alterola Biotech Financials

ABTI

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2024 Currency USD FYE March

This page shows Alterola Biotech (ABTI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ABTI FY2024 2026-04-22

External funding, not operations, appears to be carrying the business as assets collapsed and near-term obligations remained.

Between FY2023 and FY2024, total assets fell from $12.0M to $3.7K while current liabilities still measured $1.3M, so the operating base shrank far faster than the obligations attached to it. The same strain shows up in liquidity: cash was only $2.7K and the current ratio fell to 0.0x, which indicates the company was relying on something other than on-hand liquidity to meet near-term claims.

In FY2023, operating cash outflow of -$1.3M was almost backfilled by $1.2M of financing inflow, and shares outstanding later expanded from 807.0M to 1.38B. That pattern points to external capital bridging cash burn, with shareholder dilution doing part of the financing work.

The balance sheet briefly showed $9.8M of equity in FY2023, but FY2024 ended with negative equity of -$1.3M because liabilities far exceeded the remaining asset base. For a non-expert, that means the company no longer had a material asset cushion beneath those claims.

Financial Health Signals

Financial Profile 16/100

Based on FY2024 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Alterola Biotech's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Alterola Biotech carries a low D/E ratio of -1.00, meaning only $-1.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 97/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Alterola Biotech's current ratio of 0.00 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$3K

YoY-70.1%

Alterola Biotech held $3K in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

1.38B

YoY+71.3%

Alterola Biotech had 1.38B shares outstanding in fiscal year 2024. This represents an increase of 71.3% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

ABTI Income Statement

Metric	FY24	FY23	FY20	FY19	FY18	FY17
Revenue	N/A	N/A	$60K	$0	$0	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$182K	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	$68K+1254.4%	$5K+856.0%	$523+49.9%	$349+2.3%	$341
Operating Income	N/A	-$2.0M	N/A	N/A	-$123K	N/A
Interest Expense	N/A	N/A	N/A	$249-97.6%	$11K	N/A
Income Tax	N/A	N/A	$82K	N/A	$18K	N/A
Net Income	N/A	-$2.1M	N/A	N/A	-$113K	N/A
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Revenue	$0	$0	N/A	N/A	$0	$0	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$17K-11.3%	$19K	N/A	$3K	$0	$0	N/A	N/A
SG&A Expenses	$24K-44.7%	$43K	N/A	N/A	$24K+275.8%	$6K	N/A	-$28K
Operating Income	-$477K+30.1%	-$683K	N/A	N/A	-$123K+79.0%	-$585K	N/A	-$541K
Interest Expense	$337K	N/A	N/A	N/A	$337K	N/A	N/A	N/A
Income Tax	$0	$0	N/A	N/A	$0	N/A	N/A	N/A
Net Income	-$799K-22.1%	-$655K	N/A	N/A	-$123K+72.5%	-$447K	N/A	-$535K
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0.00

ABTI Balance Sheet

Metric	FY24	FY23	FY20	FY19	FY18	FY17
Total Assets	$4K-100.0%	$12.0M+78773.3%	$15K+3.6%	$15K-70.9%	$51K+19567.4%	$258
Current Assets	$4K-92.1%	$46K+203.2%	$15K+3.6%	$15K-70.9%	$51K	N/A
Cash & Equivalents	$3K-70.1%	$9K	$0	$0	$0	$0
Inventory	$1K+1.9%	$990	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.3M-41.7%	$2.3M+575.1%	$338K+55.7%	$217K+104.5%	$106K-63.9%	$295K
Current Liabilities	$1.3M-37.4%	$2.1M+529.4%	$338K+55.7%	$217K+151.8%	$86K-70.7%	$295K
Long-Term Debt	N/A	N/A	N/A	$0-100.0%	$20K	$0
Total Equity	-$1.3M-113.6%	$9.8M+3120.0%	-$323K-59.4%	-$203K-264.8%	-$56K+81.1%	-$295K
Retained Earnings	-$12.4M-23.6%	-$10.0M-721.9%	-$1.2M-25.8%	-$971K-125.7%	-$430K+25.7%	-$580K

Metric	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Total Assets	$1.4M+39.9%	$975K+26523.7%	$4K+2.1%	$4K-99.3%	$497K-96.1%	$12.7M+5.4%	$12.0M-1.3%	$12.2M
Current Assets	$1.1M+60.4%	$715K+19427.0%	$4K+2.1%	$4K-98.2%	$197K-14.7%	$231K+399.2%	$46K-75.9%	$192K
Cash & Equivalents	$83K-88.4%	$714K+26812.7%	$3K+3.1%	$3K-71.7%	$9K-75.1%	$37K+311.1%	$9K-30.6%	$13K
Inventory	$1K+5.7%	$1K+0.2%	$1K-0.6%	$1K+4.1%	$975-3.4%	$1K+1.9%	$990+2.4%	$967
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.6M+48.2%	$2.4M+83.0%	$1.3M-1.9%	$1.4M-46.1%	$2.5M+7.9%	$2.3M+2.1%	$2.3M+15.8%	$2.0M
Current Liabilities	$3.6M+48.2%	$2.4M+83.0%	$1.3M-1.9%	$1.4M-46.1%	$2.5M+7.9%	$2.3M+9.6%	$2.1M+16.9%	$1.8M
Long-Term Debt	N/A	N/A	N/A	N/A	$20K	N/A	N/A	N/A
Total Equity	-$2.1M-49.4%	-$1.4M-3.5%	-$1.3M+1.9%	-$1.4M+33.0%	-$2.0M-119.9%	$10.2M+4.1%	$9.8M-4.6%	$10.2M
Retained Earnings	-$13.7M-5.3%	-$13.0M-4.6%	-$12.4M+0.2%	-$12.4M-19.3%	-$10.4M-1.3%	-$10.3M-2.5%	-$10.0M-5.1%	-$9.6M

ABTI Cash Flow Statement

Metric	FY24	FY23	FY20	FY19	FY18	FY17
Operating Cash Flow	N/A	-$1.3M-2514.5%	-$50K	$0+100.0%	-$20K	$0
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	-$140K	$0	$0	$0	$0
Financing Cash Flow	N/A	$1.2M+2298.1%	$50K	$0	$0	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Operating Cash Flow	-$861K-315.4%	-$207K	N/A	N/A	-$508K-263.6%	$311K+306.2%	-$151K+81.0%	-$793K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$60K	$0	N/A	N/A	$202K+221.0%	-$167K-37.2%	-$122K	N/A
Financing Cash Flow	$400K-56.7%	$923K	N/A	N/A	$114K+396.0%	-$39K-136.5%	$106K-86.7%	$796K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	$0	N/A	N/A	N/A	$0

ABTI Financial Ratios

Metric	FY24	FY23	FY20	FY19	FY18	FY17
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-21.2%	N/A	N/A	N/A	N/A
Return on Assets	N/A	-17.2%	N/A	N/A	-222.8%	N/A
Current Ratio	0.00-0.0	0.02-0.0	0.05-0.0	0.07-0.5	0.59	N/A
Debt-to-Equity	-1.00-1.2	0.23+1.3	-1.05-1.0	0.00+0.4	-0.36-0.4	0.00
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	-4.4%	N/A	-5.2%
Return on Assets	-58.6%+8.6pp	-67.1%	N/A	N/A	-24.8%-21.3pp	-3.5%	N/A	-4.4%
Current Ratio	0.32+0.0	0.29+0.3	0.000.0	0.00-0.1	0.08-0.0	0.10+0.1	0.02-0.1	0.11
Debt-to-Equity	-1.76+0.0	-1.77-0.8	-1.000.0	-1.00-1.0	-0.01-0.2	0.230.0	0.23+0.0	0.19
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$1.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Canaquest Medica CANQF

$296K

Hempamericana HMPQ

$292K

Indoor Harvest INQD

$321K

Arev Life Sciences Global Corp AREVF

$318K

Lowell Farms LOWLF

$309K

Frequently Asked Questions

What are Alterola Biotech's total assets?

Alterola Biotech (ABTI) had $4K in total assets as of fiscal year 2024, including both current and long-term assets.

How many shares does Alterola Biotech have outstanding?

Alterola Biotech (ABTI) had 1.38B shares outstanding as of fiscal year 2024.

What is Alterola Biotech's current ratio?

Alterola Biotech (ABTI) had a current ratio of 0.00 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.

What is Alterola Biotech's debt-to-equity ratio?

Alterola Biotech (ABTI) had a debt-to-equity ratio of -1.00 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

Why is Alterola Biotech's debt-to-equity ratio negative or unusual?

Alterola Biotech (ABTI) has negative shareholder equity of -$1.3M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

How financially healthy is Alterola Biotech?

Alterola Biotech (ABTI) scores 16 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.